These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27432877)

  • 81. Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.
    Usmani S; Sexton R; Crowley J; Barlogie B
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):139-42. PubMed ID: 21454216
    [TBL] [Abstract][Full Text] [Related]  

  • 82. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Khan AM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629099
    [TBL] [Abstract][Full Text] [Related]  

  • 84. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
    Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
    Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.
    Berentsen S
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):110-2. PubMed ID: 19362990
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.
    Grunenberg A; Buske C
    Dtsch Arztebl Int; 2017 Nov; 114(44):745-751. PubMed ID: 29169431
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Waldenstrom macroglobulinemia: prognosis and management.
    Oza A; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
    Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
    Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Waldenström's macroglobulinemia and its individualized therapy options].
    Szemlaky Z; Mikala G
    Orv Hetil; 2017 Oct; 158(41):1604-1614. PubMed ID: 29025291
    [TBL] [Abstract][Full Text] [Related]  

  • 91. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 92. Novel treatment regimens for Waldenström's macroglobulinemia.
    García-Sanz R; Ocio EM
    Expert Rev Hematol; 2010 Jun; 3(3):339-50. PubMed ID: 21082984
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
    Chaudhry M; Steiner R; Claussen C; Patel K; Lee H; Weber D; Thomas S; Feng C; Amini B; Orlowski R; Feng L; Manasanch EE
    Leuk Lymphoma; 2019 Apr; 60(4):964-970. PubMed ID: 30227761
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline.
    Amaador K; Kersten MJ; Minnema MC; Vos JMI
    Hemasphere; 2022 Jul; 6(7):e746. PubMed ID: 35813102
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Novel agents in Waldenstrom Macroglobulinemia.
    Sacco A; Leleu X; Rossi G; Ghobrial IM; Roccaro AM
    Open J Hematol; 2010 May; 1():. PubMed ID: 22844582
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia?
    Sarosiek S; Treon SP; Branagan AR; Castillo JJ
    J Clin Oncol; 2023 Aug; 41(24):4059-4060. PubMed ID: 37348023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.